Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Altaweel MM; Pegaptanib in Central Retinal Vein Occlusion Study Group. Wroblewski JJ, et al. Among authors: katz b. Arch Ophthalmol. 2009 Apr;127(4):374-80. doi: 10.1001/archophthalmol.2009.14. Arch Ophthalmol. 2009. PMID: 19365011 Clinical Trial.
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, et al. Among authors: katz b. Ophthalmology. 2006 Jun;113(6):992-1001.e6. doi: 10.1016/j.ophtha.2006.02.027. Epub 2006 Apr 27. Ophthalmology. 2006. PMID: 16647134 Clinical Trial.
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, et al. Among authors: katz b. Ophthalmology. 2006 Sep;113(9):1508.e1-25. doi: 10.1016/j.ophtha.2006.02.064. Epub 2006 Jul 7. Ophthalmology. 2006. PMID: 16828500 Clinical Trial.
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D. Singerman LJ, et al. Among authors: katz b. Br J Ophthalmol. 2008 Dec;92(12):1606-11. doi: 10.1136/bjo.2007.132597. Epub 2008 Jul 9. Br J Ophthalmol. 2008. PMID: 18614570 Free PMC article. Clinical Trial.
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; Macugen Diabetic Retinopathy Study Group. Cunningham ET Jr, et al. Among authors: katz b. Ophthalmology. 2005 Oct;112(10):1747-57. doi: 10.1016/j.ophtha.2005.06.007. Ophthalmology. 2005. PMID: 16154196 Clinical Trial.
Basic Science and Pathogenesis.
Koutures A, Katz B, Hwang K, Cohn W, Addo-Osafo K, Vossel K. Koutures A, et al. Among authors: katz b. Alzheimers Dement. 2024 Dec;20 Suppl 1:e089653. doi: 10.1002/alz.089653. Alzheimers Dement. 2024. PMID: 39751071
1,463 results